Systemic TGF‐β blockade in the host can lead to reduced cytostatic effects of TGF‐β on tumor cells [128], but targeted blockade of TGF‐β signaling in T cells may provide a better strategy to enhance antitumor immunity and eradicate lung cancer (Fig. 6). The gene discussed is TGFB1; the disease is lung carcinoma.